Extended Data Fig. 1: Nucleocapsid antibody responses.
From: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
Nucleocapsid antibody responses at month 8 following final vaccination with Ad26.COV2.S (N = 20) or BNT162b2 (N = 27) by meso-scale discovery (MSD) electrochemoluminscent assay. SARS-CoV-2 convalescent and pre-pandemic samples were included as positive and negative controls, respectively. Relative light units are shown.
